JP7840517B2 - 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 - Google Patents

二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Info

Publication number
JP7840517B2
JP7840517B2 JP2023515057A JP2023515057A JP7840517B2 JP 7840517 B2 JP7840517 B2 JP 7840517B2 JP 2023515057 A JP2023515057 A JP 2023515057A JP 2023515057 A JP2023515057 A JP 2023515057A JP 7840517 B2 JP7840517 B2 JP 7840517B2
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
cycloalkyl
alkynyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023515057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540344A5 (enExample
JP2023540344A (ja
Inventor
ブルース レフカー
カール ギブソン
マシュー スペンディフ
ポール ハンフリーズ
サラ バックネル
ヴォイチェフ ザヴォドニー
ロデリック ポーター
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2023540344A publication Critical patent/JP2023540344A/ja
Publication of JP2023540344A5 publication Critical patent/JP2023540344A5/ja
Application granted granted Critical
Publication of JP7840517B2 publication Critical patent/JP7840517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023515057A 2020-09-03 2021-09-03 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 Active JP7840517B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074216P 2020-09-03 2020-09-03
US63/074,216 2020-09-03
PCT/US2021/049021 WO2022051596A1 (en) 2020-09-03 2021-09-03 Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists

Publications (3)

Publication Number Publication Date
JP2023540344A JP2023540344A (ja) 2023-09-22
JP2023540344A5 JP2023540344A5 (enExample) 2024-10-02
JP7840517B2 true JP7840517B2 (ja) 2026-04-06

Family

ID=78078375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515057A Active JP7840517B2 (ja) 2020-09-03 2021-09-03 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Country Status (6)

Country Link
US (1) US12503475B2 (enExample)
EP (1) EP4208444A1 (enExample)
JP (1) JP7840517B2 (enExample)
CN (1) CN116583502A (enExample)
TW (1) TW202227397A (enExample)
WO (1) WO2022051596A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
CN119156375A (zh) * 2022-03-01 2024-12-17 森特萨制药(英国)有限公司 双环杂环衍生物和相关用途
CN115124410B (zh) * 2022-08-13 2024-06-04 上海珂华生物科技有限公司 一种2-氟-4-羟基苯甲醛的制备方法
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素２型受體促效劑之給藥
JPWO2024128305A1 (enExample) 2022-12-16 2024-06-20
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) * 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
GB202404750D0 (en) 2024-04-03 2024-05-15 Bial Portela & Ca Sa Orexin receptor agonists
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229495A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20260012686A (ko) * 2024-07-18 2026-01-27 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도
WO2026114912A1 (en) 2024-11-27 2026-06-04 H. Lundbeck A/S Orexin 2 receptor agonists
WO2026114911A1 (en) 2024-11-27 2026-06-04 H. Lundbeck A/S Orexin 2 receptor agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532916A (ja) 2009-07-15 2012-12-20 ロッタファーム エス．ピー．エー． 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物
JP2015502385A (ja) 2011-12-21 2015-01-22 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化学化合物
WO2019027069A1 (ko) 2017-08-03 2019-02-07 (주)상아프론테크 연료전지 전해질 강화막 및 이의 제조방법
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2023540350A (ja) 2020-09-03 2023-09-22 センテッサ ファーマシューティカルズ （オレキシア） リミテッド 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
CA2684169C (en) 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8871794B2 (en) 2008-06-04 2014-10-28 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
NO2513053T3 (enExample) 2009-12-18 2018-03-03
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
EP2763532B1 (en) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
CN105916500A (zh) 2013-11-27 2016-08-31 欧洲筛选有限公司 用于治疗炎性疾病的化合物、药物组合物和方法
MA40404A (fr) 2014-08-05 2017-06-14 Alios Biopharma Inc Polythérapie pour traiter un paramyxovirus
WO2016021629A1 (ja) 2014-08-06 2016-02-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US10428023B2 (en) * 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
WO2021048822A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
JPWO2021065893A1 (enExample) 2019-09-30 2021-04-08
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
PE20221730A1 (es) 2019-11-27 2022-11-07 Sumitomo Pharma Co Ltd Derivado de cicloalquilurea
US20210200298A1 (en) 2019-12-30 2021-07-01 Advanced Micro Devices, Inc. Long-idle state system and method
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
WO2023017180A1 (en) 2021-08-13 2023-02-16 Orexia Therapeutics Limited Peptide derivatives and related uses as orexin agonists
CN119156375A (zh) 2022-03-01 2024-12-17 森特萨制药(英国)有限公司 双环杂环衍生物和相关用途
WO2023167925A1 (en) 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532916A (ja) 2009-07-15 2012-12-20 ロッタファーム エス．ピー．エー． 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物
JP2015502385A (ja) 2011-12-21 2015-01-22 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化学化合物
WO2019027069A1 (ko) 2017-08-03 2019-02-07 (주)상아프론테크 연료전지 전해질 강화막 및 이의 제조방법
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2023540350A (ja) 2020-09-03 2023-09-22 センテッサ ファーマシューティカルズ （オレキシア） リミテッド 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用

Also Published As

Publication number Publication date
TW202227397A (zh) 2022-07-16
WO2022051596A8 (en) 2022-04-07
EP4208444A1 (en) 2023-07-12
CN116583502A (zh) 2023-08-11
WO2022051596A1 (en) 2022-03-10
US20230271973A1 (en) 2023-08-31
US12503475B2 (en) 2025-12-23
JP2023540344A (ja) 2023-09-22

Similar Documents

Publication Publication Date Title
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
JP2023540344A (ja) 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
TWI753946B (zh) 具有ｇｌｐ-１受體促效作用的吡唑并吡啶衍生物
CN111094288B (zh) 具有mgat-2抑制活性的稠合环衍生物
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN104918935B (zh) 二氢吡唑gpr40调节剂
CN110520423A (zh) 作为激酶抑制剂的氨基三唑并吡啶
HK1249509A1 (zh) 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
CN113754654A (zh) 咪唑并吡啶类化合物及其用途
AU2002357264A1 (en) Pyrrolidine and piperidine derivates as nk1 antagonists
CN101238127A (zh) 嘧啶或三嗪稠合的二环金属蛋白酶抑制剂
TW202400606A (zh) 中環或大環之經苄基取代之雜環衍生物及相關用途
CN117042769A (zh) 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
WO2025228373A1 (zh) 一种pan-RAS抑制剂化合物
CN114423758A (zh) 抗细菌化合物
CN119156375A (zh) 双环杂环衍生物和相关用途
CN110461838A (zh) 噁二唑瞬时受体电位通道抑制剂
TW202200565A (zh) 抗病毒性1,3-二氧代茚化合物
TWI902994B (zh) Ｉｒａｋ４抑制劑、藥物組成物及其用途
TW202132288A (zh) Ｔｒｅｋ（ｔｗｉｋ相關的ｋ＋通道）通道功能的調節劑
CN114981270B (zh) Mll1抑制剂和抗癌剂
KR20230083276A (ko) 오토탁신 억제제 화합물
CN114685453A (zh) 杂环脯氨酰胺衍生物
CN108026069A (zh) 2,3,4,5-四氢吡啶-6-胺衍生物
CN113056455A (zh) 异噁唑甲酰胺化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240902

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260204

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7840517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150